Literature DB >> 34088878

Secondary Progressive Multiple Sclerosis: New Insights.

Bruce Anthony Campbell Cree1, Douglas L Arnold2, Jeremy Chataway3,4, Tanuja Chitnis5, Robert J Fox6, Angela Pozo Ramajo7, Niamh Murphy8, Hans Lassmann9.   

Abstract

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive multiple sclerosis (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunological, or pathological criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools which, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS.
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Entities:  

Year:  2021        PMID: 34088878     DOI: 10.1212/WNL.0000000000012323

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  NAD+ metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity.

Authors:  Tom Meyer; Dor Shimon; Sawsan Youssef; Gal Yankovitz; Adi Tessler; Tom Chernobylsky; Anat Gaoni-Yogev; Rita Perelroizen; Noga Budick-Harmelin; Lawrence Steinman; Lior Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-22       Impact factor: 12.779

2.  Differences in Age-related Retinal and Cortical Atrophy Rates in Multiple Sclerosis.

Authors:  Christian Cordano; Bardia Nourbakhsh; Hao H Yiu; Nico Papinutto; Eduardo Caverzasi; Ahmed Abdelhak; Frederike C Oertel; Alexandra Beaudry-Richard; Adam Santaniello; Simone Sacco; Daniel J Bennett; Apraham Gomez; Christina J Sigurdson; Stephen L Hauser; Roberta Magliozzi; Bruce A C Cree; Roland G Henry; Ari J Green
Journal:  Neurology       Date:  2022-08-29       Impact factor: 11.800

Review 3.  Thinking outside the box: non-canonical targets in multiple sclerosis.

Authors:  Laura Bierhansl; Hans-Peter Hartung; Orhan Aktas; Tobias Ruck; Michael Roden; Sven G Meuth
Journal:  Nat Rev Drug Discov       Date:  2022-06-06       Impact factor: 112.288

4.  Repurposing Histaminergic Drugs in Multiple Sclerosis.

Authors:  Susanna Amadio; Federica Conte; Giorgia Esposito; Giulia Fiscon; Paola Paci; Cinzia Volonté
Journal:  Int J Mol Sci       Date:  2022-06-06       Impact factor: 6.208

Review 5.  Neuropathic Pain in Multiple Sclerosis and Its Animal Models: Focus on Mechanisms, Knowledge Gaps and Future Directions.

Authors:  Ersilia Mirabelli; Stella Elkabes
Journal:  Front Neurol       Date:  2021-12-16       Impact factor: 4.003

Review 6.  Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype.

Authors:  Bruno Brochet; Pierre Clavelou; Gilles Defer; Jérôme De Seze; Céline Louapre; Eloi Magnin; Aurélie Ruet; Catherine Thomas-Anterion; Patrick Vermersch
Journal:  Brain Sci       Date:  2022-01-29

7.  Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod.

Authors:  Magdalena Krbot Skorić; Dunja Rogić; Ivana Lapić; Dragana Šegulja; Mario Habek
Journal:  Mult Scler Relat Disord       Date:  2021-11-29       Impact factor: 4.339

8.  Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis.

Authors:  Daniel Jons; Henrik Zetterberg; Martin Biström; Lucia Alonso-Magdalena; Martin Gunnarsson; Magnus Vrethem; Kaj Blennow; Staffan Nilsson; Peter Sundström; Oluf Andersen
Journal:  Ann Clin Transl Neurol       Date:  2022-05-03       Impact factor: 5.430

9.  Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.

Authors:  Efthymios Dardiotis; Georgia Perpati; Mariann Borsos; Ioannis Nikolaidis; Dimitrios Tzanetakos; Georgia Deretzi; Evangelos Koutlas; Constantinos Kilidireas; Dimos Dimitrios Mitsikostas; Georgios Hadjigeorgiou; Nikolaos Grigoriadis
Journal:  Neurol Ther       Date:  2022-07-13

10.  S100B Protein as a Therapeutic Target in Multiple Sclerosis: The S100B Inhibitor Arundic Acid Protects from Chronic Experimental Autoimmune Encephalomyelitis.

Authors:  Chiara Camponeschi; Maria De Carluccio; Susanna Amadio; Maria Elisabetta Clementi; Beatrice Sampaolese; Cinzia Volonté; Maria Tredicine; Vincenzo Romano Spica; Rosa Di Liddo; Francesco Ria; Fabrizio Michetti; Gabriele Di Sante
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.